Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer

This is a multicenter, open-label, multi-cohort Phase II exploratory study designed to evaluate the efficacy and safety of sacituzumab tirumotecan with or without tislelizumab in patients with unresectable, locally advanced, or metastatic anaplastic thyroid carcinoma (ATC), poorly differentiated thyroid carcinoma (PDTC), or radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Patients with ATC will receive sacituzumab tirumotecan in combination with tislelizumab. Patients with PDTC and RAIR-DTC will receive sacituzumab tirumotecan monotherapy. The primary objective in the

Trial Details

NCT ID
NCT07068542
Phase
NA
Sponsor
Zhejiang Provincial People's Hospital
Status
RECRUITING
Cancer Type
Thyroid Cancer
Interventions
  • Sacituzumab Tirumotecan (SKB264) plus Tislelizumab
  • Sacituzumab Tirumotecan (SKB264)
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Participants must meet all of the following criteria:
  • 1\. Age ≥ 18 years at the time of informed consent. 2. Histologically confirmed unresectable, locally advanced, or metastatic:
  • Anaplastic thyroid carcinoma (ATC), or
  • Poorly differentiated thyroid carcinoma (PDTC), or

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Thyroid Cancer Trials on Trialify →